Descripción del proyecto
Centrarse en los mecanismos de resistencia a los fármacos antineoplásicos
La resistencia a los fármacos antineoplásicos representa el principal obstáculo al éxito del tratamiento a largo plazo y la recuperación de los pacientes con cáncer. Scandion Oncology, una empresa de Dinamarca, está desarrollando un nuevo fármaco (SCO-101) que lucha de forma eficaz contra varios de los mecanismos de resistencia molecular más frecuentes del cáncer. SCO-101 ha superado con éxito cuatro estudios clínicos de fase 1 llevados a cabo en voluntarios sanos. El objetivo del proyecto SCANRESIST, financiado con fondos europeos, consiste en llevar a cabo estudios de validación clínica en pacientes con cáncer resistente al taxano en el marco de un ensayo clínico prospectivo de fase 2 abierto para establecer la prueba de concepto de SCO-101 como tratamiento eficaz y seguro. SCO-101 representa un cambio de paradigma al actuar a través de varios mecanismos para interferir con la resistencia a los fármacos.
Objetivo
Worldwide in 2018, cancer has been responsible for around 9.6 million deaths, and with a prediction of a further increase in incidence over the next years – which calls for urgent better treatment modalities to combat such deadly disease. Resistance to anticancer therapy is considered the main obstacle to successful clinical management of cancer patients. Scandion Oncology A/S (SCANDION) is a clinical-stage biotechnology company aimed to solve the anti-cancer drug resistance problem. We are developing a new drug, the SCO-101, which effectively targets some of the most common molecular resistance mechanisms in cancer. SCO-101 represent a paradigm shift in treatment of drug-resistant cancer, with multi mechanisms of actions in interfering with drug resistance. SCO-101 has previously passed four clinical phase I studies in healthy volunteers and proved to be a safe oral drug with very limited toxicity. The SCANRESIST project aims at performing clinical validation studies in taxane resistant breast cancer patients with open-labelled Phase II prospective clinical trial to establish SCO-101 Proof of Concept as a safe and efficient treatment modality.
Our business model is based on out-licensing SCO-101 to pharma players active in anti-cancer drugs – who will be responsible for the remaining clinical development and market launch. The Phase II clinical validation has been pointed as a critical step achieve a deal with big pharma partners/licensees, which we know are interested in novel drugs with novel MoA, and with well-designed and well-performed phase II studies with positive results. Thus, the project will not only open a large market for SCANDION as it will also allow us to position the company as a unique provider of a new generation of anti-cancer resistance drugs – continuing our path on developing other drugs to combat drug resistance in cancer, innovative trial designs, predictive biomarkers and biomarker endpoints.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-1
Régimen de financiación
SME-1 - SME instrument phase 1Coordinador
2100 KOBENHAVN
Dinamarca
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.